accountBiogen Idec Inc.'s first-quarter profits rose 35% on growth of its multiple sclerosis drug portfolio, but that performance was trumped by important new data on its oral MS treatment BG-12. The new data showed the strong effectiveness of the drug for the...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biogen Posts 35% Profit Gain, Details Strong MS Pill Data
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account